Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC-U02
- Development stage
- Unknown
- Lead developer
- Sunnycell Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SC-U02 is an allogeneic, non-viral genome-targeted chimeric antigen receptor T-cell (CAR-T) therapy developed by Sunnycell Therapeutics for the treatment of B-cell malignancies, specifically relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Engineered using CRISPR-Cas9, SC-U02 features a knockout of the T-cell receptor (TCR) gene to prevent graft-versus-host disease (GvHD) and a knockout of the beta-2-microglobulin (B2M) gene to prevent host-versus-graft rejection. To protect the cells from natural killer (NK) cell-mediated rejection caused by the lack of HLA class I expression, an artificial B2M-HLA-E fusion gene is inserted along with the anti-CD19 CAR gene directly into the TRAC locus. This design allows SC-U02 to persist in vivo without requiring CD52-targeted lymphodepletion.
- Other names
- nvGT UCART19
Beyond the preview
Go deeper on SC-U02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC-U02.